Education
About Us
Working with TipRanks
Follow Us
Aethlon Medical Inc (AEMD)
NASDAQ:AEMD
Top Page
Aethlon Medical
(NASDAQ:AEMD)
23Underperform
Positive Factors
Clinical Trials
Significant progress was made with Aethlon's oncology program, including the first treatment of a patient with the company's Hemopurifier.
Financial Management
AEMD has taken measures to improve operating expense management, which is expected to extend its cash runway and support ongoing clinical activities.
Regulatory and Market Expansion
Two hospitals in Australia are open for patient enrollment, and additional sites in Australia and India have received ethics committee approval.
Negative Factors
Investment Risks
Risks to the investment thesis include failure of clinical trials, regulatory requirements for additional clinical studies, and the potential to raise additional funds under poor market conditions.
Regulatory and Commercialization Challenges
There is uncertainty regarding the potential approval and commercialization of the Hemopurifier in the oncology and organ transplant markets.
Revenue and Forecast
Despite clinical progress and financial discipline, AEMD did not recognize any revenue during the F3Q25 quarter, and no revenue is forecasted for FY25 or FY26.
Aethlon Medical (AEMD) vs. S&P 500 (SPY)
Market Cap
$7.24M
Dividend YieldN/A
Average Volume (3M)167.47K
Price to Earnings (P/E)―
Beta (1Y)1.20
Revenue Growth-100.00%
EPS Growth68.26%
CountryUS
Employees14
SectorHealthcare
Sector Strength77
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.59
Shares Outstanding20,657,097
10 Day Avg. Volume90,444
30 Day Avg. Volume167,467
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.00Price Target Upside1900.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Aethlon Medical Business Overview & Revenue Model
Company DescriptionAethlon Medical, Inc. (AEMD) is a biotechnology company focused on developing innovative therapies for life-threatening diseases. The company primarily operates in the healthcare sector, offering medical devices and therapeutic solutions aimed at addressing unmet medical needs, particularly in the areas of oncology and infectious diseases. Aethlon's flagship product, the Hemopurifier, is a first-in-class device designed to selectively filter and remove harmful viruses and exosomes from the bloodstream, which can contribute to disease progression and immune suppression.
How the Company Makes MoneyAethlon Medical makes money through the development and commercialization of its Hemopurifier product, targeting both therapeutic and diagnostic markets. Revenue is primarily generated from grants, research and development contracts, and potential sales or licensing of its proprietary technology. As a company focused on early-stage biotechnology, Aethlon also relies on government funding and partnerships with research institutions to support its development efforts. Key factors contributing to its earnings include the expansion of its product applications, regulatory approvals, and strategic collaborations that enhance its market reach and product development pipeline.
Aethlon Medical Financial Statement Overview
Summary
Aethlon Medical faces significant financial challenges, with no revenue growth and persistent losses. The balance sheet suggests limited financial flexibility despite low leverage. Cash flow issues exacerbate these concerns, with substantial cash outflows overshadowing financing efforts. The company needs to address its revenue generation and operational efficiency to improve its financial standing.Income Statement
Aethlon Medical's income statement reveals significant challenges, with consistent negative gross profit and net income across both TTM and annual reports. The absence of revenue in the latest TTM indicates a severe downturn. Persistent negative EBIT and EBITDA margins highlight ongoing operational inefficiencies, with no visible improvement in revenue growth.10
Very Negative
Balance Sheet
The balance sheet shows a moderate equity position with a relatively stable debt level. The Debt-to-Equity ratio remains low, indicating conservative leverage. However, the equity ratio suggests reliance on stockholder equity for asset financing, which could limit future growth potential. Despite a sizable cash position, the company's assets are declining, hinting at potential liquidity concerns.30
Negative
Cash Flow
Cash flow analysis indicates severe cash management issues, with negative free cash flow and operating cash flow across periods. The large discrepancy between operating cash flow and net income raises concerns about the sustainability of operations. Despite positive financing cash flow, likely from equity issuance, the free cash flow remains negative, reflecting ongoing cash burn.20
Very Negative
| Breakdown | |||||
| TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 574.25K | 294.17K | 659.10K | 650.19K | Gross Profit |
| -171.89K | -359.06K | 308.94K | 139.95K | 659.10K | 650.19K | EBIT |
| -9.82M | -12.64M | -11.90M | -10.42M | -7.89M | -5.93M | EBITDA |
| -9.37M | -11.85M | -11.66M | -10.30M | -7.85M | -6.30M | Net Income Common Stockholders |
| -9.56M | -12.21M | -12.03M | -10.42M | -7.89M | -6.37M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 67.95K | 5.44M | 14.53M | 17.07M | 9.86M | 9.60M | Total Assets |
| 646.00K | 8.25M | 17.51M | 19.42M | 10.67M | 10.39M | Total Debt |
| 1.92M | 940.32K | 1.21M | 729.41K | 42.54K | 141.10K | Net Debt |
| 1.85M | -4.50M | -13.32M | -16.34M | -9.82M | -9.46M | Total Liabilities |
| 5.05M | 2.48M | 2.44M | 2.43M | 1.38M | 1.11M | Stockholders Equity |
| -4.40M | 5.77M | 15.06M | 17.13M | 9.43M | 9.41M |
| Cash Flow | Free Cash Flow | ||||
| -5.98B | -10.38M | -11.45M | -10.12M | -6.82M | -5.35M | Operating Cash Flow |
| -5.98B | -10.13M | -10.51M | -9.77M | -6.76M | -5.20M | Investing Cash Flow |
| -2.20M | -250.87K | -943.11K | -349.19K | -59.88K | -151.66K | Financing Cash Flow |
| 5.41M | 1.29M | 8.91M | 17.37M | 7.13M | 11.13M |
Aethlon Medical Technical Analysis
Negative
0.35
Price Trends
0.53
Negative
0.52
Negative
0.47
Negative
Market Momentum
-0.04
Negative
34.03
Neutral
14.65
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AEMD, the sentiment is Negative. The current price of 0.35 is below the 20-day moving average (MA) of 0.40, below the 50-day MA of 0.53, and below the 200-day MA of 0.47, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 34.03 is Neutral, neither overbought nor oversold. The STOCH value of 14.65 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AEMD.
Aethlon Medical Risk Analysis
Aethlon Medical disclosed 59 risk factors in its most recent earnings report. Aethlon Medical reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aethlon Medical Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
48 Neutral | $6.36B | 1.14 | -49.00% | 2.63% | 17.14% | 1.39% | |
43 Neutral | $6.36M | ― | -18.06% | ― | -30.19% | 75.92% | |
43 Neutral | $9.11M | ― | -170.33% | ― | -14.79% | 76.94% | |
42 Neutral | $9.06M | ― | -809.29% | ― | ― | ― | |
35 Underperform | $6.14M | ― | 77.20% | ― | -3.76% | 39.52% | |
34 Underperform | $6.80M | ― | -21.59% | ― | ― | 71.57% | |
23 Underperform | $7.24M | ― | -160.04% | ― | -100.00% | 68.26% |
* Healthcare Sector Average
Performance Comparison
AEMD
Aethlon Medical
0.35
-1.33
-79.17%
TRIB
Trinity Biotech
0.54
-1.39
-72.02%
PPBT
Purple Biotech
2.58
1.87
263.38%
AYTU
Aytu BioScience
1.03
-2.27
-68.79%
BNGO
BioNano Genomics
3.03
-60.57
-95.24%
MYNZ
Mainz Biomed B.V.
2.98
-40.22
-93.10%
Aethlon Medical Earnings Call Summary
Earnings Call Date: Feb 12, 2025 | % Change Since: -47.76% | Next Earnings Date: Jun 26, 2025
Earnings Call Sentiment Neutral
The earnings call indicated a balanced outlook for Aethlon Medical, with significant strides in protocol amendments and cost reduction efforts. However, challenges in patient enrollment and an anticipated increase in operating expenses present ongoing hurdles.Highlights
Successful Protocol Amendment for Oncology Trial
Aethlon Medical successfully amended the protocol for its oncology trial, eliminating the two-month run-in period for patients and broadening eligibility. This amendment aims to improve enrollment speed and reduce screen failures.
Cost Reduction Achievements
Operating expenses decreased by approximately 50% to $1.8 million compared to $3.6 million the previous year, driven by reductions in payroll, professional fees, and general administrative expenses.
Approval and Expansion of Clinical Sites
The amended protocol received approval from the Human Research Ethics Committee and Research Governance Offices, and will be implemented at all three sites, with the third site in Sydney expected to commence patient enrollment soon.
Lowlights
Limited Patient Enrollment in Oncology Trial
Only three patients have been enrolled in the Australian Oncology trial, with two not advancing to the Hemopurifier treatment phase, indicating challenges in patient progression and data collection.
Potential Increase in Operating Expenses
Despite current cost reductions, operating expenses are expected to increase with the advancement of clinical trials in Australia and India, alongside potential staffing needs.
Company Guidance
During the Aethlon Medical Third Quarter Fiscal 2025 earnings call, the company provided guidance on their financial performance and clinical trial progress. As of December 31, 2024, Aethlon reported a cash balance of approximately $4.8 million. Operating expenses for the quarter decreased by around 50% to $1.8 million compared to the previous year, primarily due to a $1.3 million reduction in payroll and related expenses, a $300,000 decrease in professional fees, and a $200,000 decrease in general and administrative expenses. The company is advancing its oncology trials in Australia and India, with three patients enrolled in the Australian trial so far. The trial aims to enroll nine to 18 patients to assess the safety and feasibility of the Hemopurifier device. Aethlon is also pursuing similar trials in India, with regulatory approval pending. The company's strategic focus on reducing operating expenses while advancing high-impact clinical programs was highlighted as a key part of their strategy moving forward.Aethlon Medical Corporate Events
Business Operations and StrategyFinancial Disclosures
Aethlon Medical Achieves Milestone in Oncology Trials
Positive
Feb 12, 2025
In its recent financial release, Aethlon Medical reported a significant milestone in its oncology trials in Australia, announcing the first patient treated with the Hemopurifier for solid tumors not responding to anti-PD-1 antibodies on January 29, 2025. The company has also implemented strategic cost-cutting measures, reducing operating expenses by 50% from the previous year, and made protocol amendments to accelerate trial timelines and improve patient enrollment. These developments are crucial for enhancing the company’s clinical program efficiency and potentially improving therapeutic responses in future oncology efficacy trials.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.